Explore the vast range of titles available.

It is well accepted that young individuals on dialysis have poor clinical outcomes, although it is increasing apparent that they have similarly poor patient-centred ones. We study these latter outcomes in the population of youths undergoing dialysis in Aotearoa New Zealand (AoNZ). This study aims to report their sociodemographic and clinical characteristics, and explore their mental well-being and health-related quality of life, and how these outcomes are influenced by factors such as self-efficacy, physical activity, mood, and social anxiety. A cross-sectional survey will be conducted of youths aged 15-24 years on dialysis in AoNZ with eligible youths on dialysis across AoNZ, using validated psychometric instruments to assess daily activities, mental health, quality of life, social interactions, and self-efficacy. Open-ended questions within the survey will collect qualitative data. Clinical and demographic data will be established from clinical records and linked public health databases. Quantitative data will be analyzed using descriptive statistics and structural equation modeling to explore associations between psychometric constructs, mental well-being, and quality of life. Open-ended questions will be analysed using qualitative content analysis. Informed consent will be sought from all participants. The research will adhere to data protection guidelines, ensuring that participants' rights and confidentiality are protected. Results will be disseminated through academic publications, conferences, and summary reports provided to participants and stakeholders.

Executive coach and psychologist Marshall Goldsmith discusses the emotional triggers that set off a reaction or a behavior in us that often works to our detriment. Do you find that at times you suddenly become defensive or enraged by an idle comment from a colleague? Or that your temper rises when another car cuts you off in traffic? Your reactions don't occur in a vacuum. They are the result of emotional and psychological triggers that often happen only in specific settings -- at meetings, or in competitive situations, or with a specific person who rubs you the wrong way, or when you feel under particular pressure. Being able to recognize those triggers and understand how the environment affects our behavior is key to controlling our responses and managing others at work and in life. Make no mistake -- change is hard. And the starting point is the willingness to accept help, and the desire to change. Over the course of this book, Marshall explores the power of active questions to get us to take responsibility for our actions -- and our failure to act. Questions such as \"Did I do my best to make progress toward my goal?\" \"Did I work hard at being fully engaged?\" He discusses the importance of structure in effecting permanent change. Because, he points out, change is hard, and without a structure to keep us on track, we inevitably relapse and fall back. Filled with stories from Marshall's work with executives and leaders, Triggers shows readers how to achieve meaningful and sustained change that will allow us to open our imaginations and escape the rigidity of binary thinking.

To investigate the effect of adding clinical study report (CSR) data to publication and author data on data completeness and meta-analytical results. Case report of a systematic review with meta-analysis of randomized controlled trials on icodextrin compared to glucose solutions in peritoneal dialysis including 19 clinical trials. We considered the outcomes mortality, peritoneal dialysis technique failure, quality of life, net peritoneal ultrafiltration (at 3–6 months, and 1–2 years), serious adverse events (SAE), peritonitis, and uncontrolled fluid overload. The results for these outcomes were reanalyzed using (a) publication and author data only, then compared with (b) publication and author data with added CSR data. At outcome level, we compared the number of included trials, pooled point estimates (ie, regarding effect direction), and 95% confidence intervals (CIs; ie, regarding overlap and width) between the two groups of trials (a and b). We illustrated the results of our meta-analyses in forest plots and narratively summarized them. Except for two of the eight assessed outcomes (quality of life and net peritoneal ultrafiltration [1–2 years]), more complete data was available when adding CSRs to publication and author data. Point estimates were not statistically significantly different for publication and author data, compared to publication, author, and CSR data, for any outcome. For peritonitis, point estimates were on opposite sides of the line of no effect but remained statistically nonsignificant when adding CSR data. For SAE and net peritoneal ultrafiltration (3–6 months), the width of the 95% CI was narrower when adding CSR data and for net peritoneal ultrafiltration (3–6 months), in addition, the point estimate statistically significantly favored icodextrin when adding CSR data. The fraction of publications reporting results varied substantially by outcome, with SAE most under-reported in publications. While the integration of CSR data did not substantially alter meta-analytical results, it enhanced data completeness and precision in effect estimates. Our findings underscore the importance of accessing CSR data to optimize evidence syntheses and inform clinical decision-making. When researchers want to understand how well a treatment works, they often combine results from several clinical studies in a process called a meta-analysis. Usually, these analyses rely on data published in scientific journals. However, published articles don't always include all the important results. Additional information can sometimes be found in clinical study reports (CSRs), which are detailed documents submitted by pharmaceutical companies to regulatory agencies. In this study, we looked at how including CSR data might affect the results of a meta-analysis. We focused on 19 clinical trials that compared two types of interventions used in peritoneal dialysis for patients with kidney disease: solutions based on icodextrin, a sugar polymer, or on a sugar called glucose. We analyzed several health outcomes such as survival, quality of life, peritoneal ultrafiltration, and complications like infections or kidney function, and serious side effects. First, we analyzed the results using only published articles and information provided by study authors. Then we repeated the analysis, this time adding data from CSRs where available. We compared the number of studies included, the size and direction of treatment effects, and the precision of the results. We found that adding CSRs often provided more complete information, especially for outcomes like serious side effects that were not always reported in journal articles. The overall direction of the results—whether icodextrin was better, worse, or the same—did not change much when CSR data was added. However, the results became more precise in two cases (serious side effects and peritoneal ultrafiltration). In one case, adding CSR data made the benefit of icodextrin statistically significant (peritoneal ultrafiltration). In summary, although adding CSR data did not substantially change the main conclusions, it improved the completeness and accuracy of the results. This shows that using CSRs in research summaries can provide a more reliable basis for making clinical decisions. •Adding CSR data did not lead to significantly different point estimates in meta-analysis.•Integration of CSR data enhanced data completeness and precision of effect estimates.•The structured nature and detailed reporting of CSRs facilitates data retrieval.•Trial sponsors should make full CSRs publicly available without restriction.•Systematic reviewers should search for and include CSRs.

Your hard work is paying off. You are doing well in your field. But something is standing between you and the next level of achievement. That something may be one of your annoying habits. Perhaps one small flaw - a behavior you barely even recognize - is the only thing that's keeping you from where you want to be. It may be that the very characteristic that you believe got you where you are - like the drive to win at all costs is what's holding you back. As this book explains, people often do well in spite of certain habits rather than because of them - and need a \"to stop\" list rather than one listing what \"to do.\" Marshall Goldsmith's expertise is in helping global leaders overcome their annoying unconscious habits and become more successful. His one-on-one coaching comes with a six-figure price tag - but in this book, you get his great advice for much less. Recently named as one of the world's five most-respected executive coaches by Forbes, he has worked with over 100 major CEOs and their management teams at the world's top businesses. His clients include corporations such as Goldman Sachs, Glaxo SmithKline, Johnson and Johnson, and GE.

Intravenous (IV) iron is required for optimal management of anemia in the majority of hemodialysis (HD) patients. While IV iron prescription has increased over time, the best dosing strategy is unknown and any effect of IV iron on survival is unclear. Here we used adjusted Cox regression to analyze associations between IV iron dose and clinical outcomes in 32,435 HD patients in 12 countries from 2002 to 2011 in the Dialysis Outcomes and Practice Patterns Study. The primary exposure was total prescribed IV iron dose over the first 4 months in the study, expressed as an average dose/month. Compared with 100–199mg/month (the most common dose range), case-mix-adjusted mortality was similar for the 0, 1–99, and 200–299mg/month categories but significantly higher for the 300–399mg/month (HR of 1.13, 95% CI of 1.00–1.27) and 400mg/month or more (HR of 1.18, 95% CI of 1.07–1.30) groups. Convergent validity was proved by an instrumental variable analysis, using HD facility as the instrument, and by an analysis expressing IV iron dose/kg body weight. Associations with cause-specific mortality (cardiovascular, infectious, and other) were generally similar to those for all-cause mortality. The hospitalization risk was elevated among patients receiving 300mg/month or more compared with 100–199mg/month (HR of 1.12, 95% CI of 1.07–1.18). In light of these associations, a well-powered clinical trial to evaluate the safety of different IV iron-dosing strategies in HD patients is urgently needed.

In this edition of 'Sales Force Management', Mark Johnston and Greg Marshall continue to build on the tradition of excellence established by Churchill, Ford, and Walker, solidifying the book's position globally as the leading textbook in the field. Including the Churchill, Ford, and Walker approach, this new edition also features a strong focus on leadership, technology, innovation, ethics, and global business.

Most haptic actuators available on the market today can generate only a single modality of stimuli. This ultimately limits the capacity of a kinaesthetic haptic controller to deliver more expressive feedback, requiring a haptic controller to integrate multiple actuators to generate complex haptic stimuli, with a corresponding complexity of construction and control. To address this, we designed a haptic controller to deliver several modalities of kinaesthetic haptic feedback using a single actuator: a flywheel, the orientation of which is controlled by two gimbals capable of rotating over 360 degrees, in combination with a flywheel brake. This enables the controller to generate multiple haptic feedback modalities, such as torque feedback, impact simulation, low-frequency high-amplitude vibrations, inertial effects (the sensation of momentum), and complex haptic output effects such as the experience of vortex-like forces (whirl effects). By combining these diverse haptic effects, the controller enriches the haptic dimension of VR environments. This paper presents the device’s design, implementation, and characterization, and proposes potential applications for future work.

يؤدي هذا الكتاب دور دليل مهم يساعدك على التخلص من عيوبك وتحقيق ما تصبو إليه سواء أكنت قاب قوسين أم أدنى من القمة أم كانت أمامك بضع محطات قبل بلوغ تلك القمة. ثناء على مارشال غولدسميث \"كانت أفكار مارشال القيمة عن تطوير القيادة والمسؤوليات المرتبطة بها من تدريب وتعليم فائقة الأهمية بالنسبة لضباطنا وزوجاتهم\"-الجنرال إيريك ك. شينسكي قائد أركان الجيش الأمريكي السابق \"مارشال قادر بأسلوبه الساحر على معالجة القضايا المزعجة بطريقة مريحة. وهذا لا يودي إلى تحسن القادة وحدهم بل إلى تحسن الفريق كله !\"-جورج بورست رئيس مجلس إدارة تويوتا فاينانشال سيرفسز. \"إن مارشال غولدسميث من أفضل المدربين في العالم وبوسعه تدريب رجال الأعمال أينما كانوا\".

Augmented reality offers many artistic possibilities when it comes to the creation of place-based public artworks. In this paper, we present a series of works around the topic of augmented reality (AR) art and place-based storytelling, including the use of walking as a creative method, a series of workshops with emerging artists, public AR art collaborations and a study to examine user experience when interacting with such artworks. Our findings from these works show the potential of integrating augmented reality with public physical artworks and offer guidance to artists and AR developers on how to expand this potential. For artists, we show the importance of the space in which the artwork will be placed and provide guidance on how to work with the space. For developers, we find that there is a need to create tools that work with artists’ existing practices and to investigate how to expand augmented reality past the limitations of site- or piece-specific apps.